China's Pro-science Leaders To Make Biotech Drugs A Central Plank In New Five Year Plan
This article was originally published in PharmAsia News
You may also be interested in...
As part of China’s five-year plan, environmental restrictions will increasingly get more attention, but punishments for lax companies will likely be tougher in urban areas where public awareness is greater.
Unlike Quintile’s current offices in Beijing and Shanghai, newly launched Kun Tuo will focus solely on Chinese biopharma customers, offering them custom-tailored solutions at a competitive price point.